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Available online 10 July 2020Dengvaxia, a chimeric yellow fever tetravalent dengue vaccine developed by SanofiPasteur is widely
licensed in dengue-endemic countries. In a large cohort study Dengvaxia was found to partially protect
children who had prior dengue virus (DENV) infections but sensitized seronegative children to break-
through DENV disease of enhanced severity. In 2019, the European Medicines Agency and the US FDA
issued licenses that reconciled safety issues by restricting vaccine to individuals with prior dengue infec-
tions. Using revised Dengvaxia efficacy and safety data we sought to estimate hospitalized and severe
dengue cases among the more than 800,000 9 year-old children vaccinated in the Philippines. Despite
an overall vaccine efficacy of 69% during 4 years post-vaccination we project there will be more than
one thousand vaccinated seronegative and seropositive children hospitalized for severe dengue.
Assisting these children through a program of enhanced surveillance leading to improved care deserves
widespread support. Clinical responses observed during breakthrough dengue infections in vaccinated
individuals counsel prudence in design of vaccine policies. Recommendations concerning continued
use of this dengue vaccine are: (1) obtain a better definition of vaccine efficacy and safety through
enhanced phase 4 surveillance, (2) obtain a valid, accessible, sensitive, specific and affordable serological
test that identifies past wild-type dengue virus infection and (3) clarify safety and efficacy of Dengvaxia
in flavivirus immunes. In the absence of an acceptable serological screening test these unresolved ethical
issues suggest Dengvaxia be given only to those signing informed consent.
 2020 Elsevier Ltd. All rights reserved.Over the past 50 years dengue viruses (DENV) have expanded
from a geographic focus in Southeast Asia to achieve a global pan-
demic. These four mosquito-borne viruses circulate mostly in
urban areas in more than 100 tropical and subtropical countries
resulting in millions of infections and disease, mild to lethal, in
young and old.[1,2] The disease exacts a horrific toll. As of 30
November, the cumulative number of dengue cases during 2019
in the Philippines was 414,532 with 1,546 deaths [3]. Failure to
interrupt the transmission of dengue viruses using classical mos-
quito vector control has generated large scale efforts to developdengue vaccines. This has been complicated by an immunopatho-
logical phenomenon, sensitization to a first DENV infection that
increases the severity of a breakthrough DENV infection, antibody
dependent enhancement (ADE) [4]. The 2013 WHO Guidelines on
the quality, safety and efficacy of dengue tetravalent vaccines (live,
attenuated) warned: ‘‘There is a risk that vaccination could predis-
pose recipients to developing a severe form of dengue febrile illness
(DFI). The risk may increase with time elapsed since vaccination in
relation to waning titres of vaccine-induced antibodies in subjects
who have not been naturally boosted in the interim period. The
monitoring and investigation of all subjects who develop signs or
symptoms potentially indicative of DFI during pre-licensure studies
in endemic regions should provide a preliminary assessment of this
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jects together with further assessment of the risk in the post-
licensure period .”[5] A critical omission from the WHO Guidelines
was a requirement that children be bled prior to vaccination permit-
ting separate efficacy calculations for seronegative and seropositive
individuals.Table 1
Rates of hospitalization and severe dengue in 9–16 year-old seronegative children
given Dengvaxia or placebo during months 13–60. Seronegative population has been
expanded to 100% [25]. Estimates of 4 year DENV infections based on 15% annual
DENV infection rate (47.8% cumulative) and seronegative prevalence rates from
published data [26,27]. Month 13 serostatus is determined by dengue NS1 IgG ELISA
test, threshold 9 [25].
Categories Vaccinated Placebo
Seronegatives (observed) 3300 1710
Primary DENV infections/4 years (est.) 1577 817
Hospitalizations (observed) 56 20
Severe cases (observed) 12 1
Hospitalization rate/4 years 3.55% 2.45%
Annual hospitalization rate 0.89% 0.6%
Severe case rate/4 years 0.76% 0.12%
Annual severe case rate 0.19% 0.03%
Bolded type signifies direct or inferred published observations [25].1. Dengvaxia
Beginning in 2006, Sanofipasteur tested a novel live-attenuated
yellow fever chimeric tetravalent dengue vaccine (Dengvaxia) for
efficacy and safety in placebo-controlled clinical trials enrolling
nearly 35,000 children, ages 2–16 years, in ten dengue-endemic
countries [6]. Less than 12% of these children had been bled prior
to vaccination.[6,7] Early efficacy results were decidedly mixed.
Through year 3 post-1st dose, vaccine protection against hospital-
ization of >/= 9 year-old children was 65.5% while among children
ages 8 years or younger the rate was 44.6%.[6] For children with
serostatus known at the time of immunization, in seronegatives
vaccine protection of children 8 years and younger was 14.4%
while for those 9 and older, it was 52.5%. Despite the warnings of
the potential for vaccine-enhanced dengue disease in WHO Guide-
lines, in analyzing phase 3 results, advisory groups of the World
Health Organization initially labeled breakthrough dengue disease
in vaccinated children as ‘‘safety signals.” [8] A high rate of hospi-
talization among vaccinated 2–5 year-olds was attributed to novel,
unstudied pathogenic mechanisms such as young age, a temporal
‘‘clustering” of vaccine-related cases occurring in young children
due to the large numbers given vaccine over a short period, or to
the immunological immaturity of recipients [6,9]. These data led
the manufacturer and advisory groups to recommend vaccine be
restricted to children 9 years and older [6,10]. Further, it was rec-
ommended that vaccination be directed to populations in settings,
national and regional, with a seroprevalence of 70% or greater [11].
To provide guidance for the deployment of vaccine, WHO described
sampling and statistical methods for measuring population-based
DENV seroprevalence [12,13].
Based upon vaccine efficacy, mathematical models and WHO
recommendations, Dengvaxia achieved licensing in 20 dengue-
endemic countries [10,11,14,15]. Recently, the European Union
announced issuance of a license stipulating that ‘‘Dengvaxia will
be available in Europe to prevent dengue disease in individuals
9–45 years of age with a documented prior dengue infection and
who are living in endemic areas” [16]. Subsequently, the U.S. Food
and Drug Administration licensed Dengvaxia ‘‘for use in individu-
als 9 through 16 years of age with laboratory-confirmed previous
dengue infection and living in endemic areas” [17]. Licensing deci-
sions in the US and Europe were announced without identifying a
marketed serological test capable of sensitively detecting a past
dengue infection and distinguishing antibodies to dengue from
other flavivirus infections.
The WHO Guidelines did not define vaccine enhanced severe
dengue disease as a ‘‘serious adverse event” (SAE) and this position
remains unchanged [15,18,19]. During phase 1 and 2 studies, vac-
cine adverse events (AE) were reported in children and adults.
These were predominantly at needle inoculation sites and occurred
at rates that did not differ between dengue-immunes or non-
immunes or between controls and vaccinated [20,21]. A skin site
focus for AEs also predominated in reports from phase 3 clinical
trials. These were supplemented by additional solicited and unso-
licited symptomatic events, including diverse systemic infections.
Incidence rates of these events did not differ between vaccinated
and controls [7,22–24]. No AEs were attributed to breakthrough
DENV infections. Yet, a clinical diagnosis that can be made accu-
rately in children, hospitalization for severe dengue, has beenshown to occur at higher frequency after Dengvaxia administration
to seronegatives than in unvaccinated controls. Severe dengue was
a significant outcome of hospitalized breakthrough DENV infec-
tions in vaccinated seronegative 2–8 year-olds [25].2. Vaccination of Philippine children
In one licensing country, the Philippines, beginning in 2016,
Dengvaxia was given to 880,464 nine-year-old children (personal
communication to LRD from Secretary of Health, Philippines, 4
September 2019). After this program was initiated a novel serolog-
ical test, applied retrospectively, generated data for entire phase 3
population discovering that breakthrough dengue cases were
related to pre-immunization serostatus [25]. Seronegative children
given Dengvaxia were at significant risk to severe dengue. This
news resulted in cancelation of the vaccination program in the
Philippines and in widespread public alarm. We sought to under-
stand the likely outcomes of this vaccination program.
To do this we estimated hospitalization and severe dengue rates
in the phase 3 vaccinated and unvaccinated children, for both 9–16
and 2–8 year-olds based on revised data.[25] Estimating annual
infection rates requires DENV force of infection (FOI) data but
FOI was not measured during Phase 3 [25]. Fortuitously, prior to
initiating phase 3, Sanofi measured DENV antibody prevalence in
all 10 participating country vaccine sites. These data provided an
estimate of average annual DENV FOI of 0.155 (15.5%) over a period
of 14 years [26,27]. We applied the average annual FOI to obtain
age-specific primary DENV infection rates for a post-vaccination
period of 1 and 4 years. Observed and estimated figures for hospi-
talizations and severe dengue cases and rates in vaccinated and
unvaccinated 9–16 year -old seronegative children are shown in
Tables 1 and 2. Fifty-six dengue hospitalizations were observed
among an estimated 1577 1st DENV infections in vaccinated
seronegatives compared with 20 hospitalizations among 817 pri-
mary DENV infections among unvaccinated susceptibles. The 4-
year hospitalization rate in vaccinated children is 3.55% versus
2.45% in controls, rates that do not differ (p greater than 0.05). Sev-
ere dengue was rare in dengue infected unvaccinated 9–16 year-
olds. Only a single child among 817 primary DENV infections in
this age group was hospitalized with severe dengue, 0.12%, com-
pared with 12 severe hospitalizations among 1577 vaccinated
seronegative children, 0.76%, chi square, p < 0.05, with Yates cor-
rection, p = 0.0867 N.S (Table 1).
Crucially, there is important confirmatory evidence of vaccine
ADE among 2–8 year-old seronegatives, 25 severe dengue cases
among an estimated 1820 vaccinated versus 4 cases among an esti-
mated 1010 DENV-infected controls, p = 0.024 (Yates) (Table 3).[25]
In the phase 3 population, over a period of 4 years, hospitalization
Table 2
Rates of hospitalizations and severe dengue in 9–16 year-old seropositive children
given Dengvaxia or placebo recorded for months 13–60. Seropositive totals have been
expanded from the 10% sample. Estimates of 4 year DENV infections assume 15%
annual DENV infection (47.8%, total) and seronegative prevalence rates using
published data [26]. DENV monotypic immune prevalence of 33% is from published
data [26]. M 13 serostatus is determined by dengue NS1 IgG ELISA test, threshold 9
[25].
Categories Vaccinated Placebo
Seropositives (observed) 14,500 6870
Monotypic immunes, est. 4833 2290
2 DENV infections/4 years est. 2310 1095
2 DENV hospitalizations, (observed) 49 110
2 DENV Severe cases, (observed) 10 27
Hospitalization rate/4 years 2.1% 10.05%
Annual hospitalization rate 0.525% 2.51%
Severe case rate/4 years 0.43% 2.5%
Annual severe case rate 0.108% 0.616
Bolded type signifies direct or inferred published observations [25].
Table 3
Rates of hospitalization and severe dengue in 2–8 year-old seronegative children
given Dengvaxia or placebo during months 13–60. Seronegative population has been
expanded to 100% [25]. Estimates of 4 year DENV infections based on 15% annual
DENV infection rate (47.8% cumulative) and seronegative prevalence rates from
published data [26,27]. Month 13 serostatus is determined by dengue NS1 IgG ELISA
test, threshold 9 [25].
Categories Vaccinated Placebo
Seronegatives (observed) 1820 1010
Primary DENV infections/4 years (est.) 870 483
Hospitalizations (observed) 131 33
Severe cases (observed) 25 4
Hospitalization rate/4 years 15.1% 6.8%
Annual hospitalization rate 3.78% 1.7%
Severe case rate/4 years 6.8% 0.83%
Annual severe case rate 1.7% 0.21%
Bolded type signifies direct or inferred published observations [25].
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cinated seropositive (monotypic immune) 9–16 year-olds while in
2–8 year-old monotypic immunes these events occurred at the
astonishing rates of 15.7% and 4.4%%, respectively. (Tables 2 and 4).
To better understand issues raised in the Philippines we applied
these data to the population of nine year-olds vaccinated begin-
ning in 2016 (Table 5). Prior to the phase 3 trial, Sanofi measured
DENV seroprevalence in Philippine 9 year-olds at 85%.[26] Apply-
ing this figure to the 880,464 vaccinated children identifies
132,070 seronegatives. Of these, 63,129 would be expected toTable 4
Rates of hospitalizations and severe dengue in 2–8 year-old seropositive children
given Dengvaxia or placebo recorded for months 13–60. Seropositive totals have been
expanded from the 10% sample. Estimates of 4 year DENV infections assume 15%
annual DENV infection (47.8%, total) and seronegative prevalence rates using
published data [26]. DENV monotypic immune prevalence of 33% is from published
data [26]. M 13 serostatus is determined by dengue NS1 IgG ELISA test, threshold 9
[25].
Categories Vaccinated Placebo
Seropositives (observed) 3000 1350
Monotypic immunes, est. 1000 450
2 DENV infections/4 years est. 478 216
2 DENV hospitalizations, (observed) 75 65
2 DENV Severe cases, (observed) 21 17
Hospitalization rate/4 years 15.7% 30.0%
Annual hospitalization rate 3.9% 7.5%
Severe case rate/4 years 4.4% 7.9%
Annual severe case rate 1.1% 2.0%
Bolded type signifies direct or inferred published observations [25].experience a DENV infection during the 4 years after completion
of vaccination using our 4-year infection rate of 47.8%. Applying
hospitalization and severe dengue rates from the phase 3 study
(Table 1) to vaccinated seronegative Philippine children, yields
2241 hospitalized and 480 with severe dengue cases (Table 5).
But, DENV disease also was observed in vaccinated seroposi-
tives. It is well established that nearly all hospitalizations of
seropositive children occur during a second heterotypic dengue
infection.[28] Seropositive children at risk to dengue hospitaliza-
tion are monotypic immunes. From published measurements,
33% of Philippine 9 year olds were monotypic immunes.[26]
Among an estimated 290,553 vaccinated monotypic immunes
infected with DENV over 4 years (47.8%), there will be 138,884 sec-
ondary DENV infections resulting in 2917 hospitalizations and 597
severe cases (Table 5). Total hospitalizations and severe cases
among seronegatives and seropositives are 5158, and 1077, respec-
tively. Using a similar approach WHO staff and advisory groups
recently estimated breakthrough clinical dengue disease among
children vaccinated in the Philippines for a period of 5 years after
the first dose.[29,30] Our data, for the 4 years after completion of
vaccination are similar.
What are the trade-offs? Howmany hospitalizations and severe
dengue cases were prevented by vaccine? Among an estimated
290,553 monotypic immunes infected over 4-years (47.8%) there
would be 138,884 secondary DENV infections resulting in 13,958
hospitalizations and 3472 severe cases (Table 5). But, unvaccinated
DENV-infected seronegatives (63,129) also experience DENV dis-
ease, 1547 hospitalizations and 75 severe cases. Totals for unvacci-
nated are 15,505 hospitalized and 3547 severe cases, compared
with 5158 hospitalizations and 1077 severe cases in vaccinated
children, a 67–69% vaccine efficacy, identical to other estimates.
[30]3. Dengvaxia, safety concerns
Based upon our estimates, during the first four years after com-
plete Dengvaxia immunization a significant segment of children
vaccinated in 2016 will have been protected from severe dengue
disease. During that same period, however, nearly 500 vaccinated
seronegative children are expected to acquire severe dengue. What
do we owe them? Public health workers are confronted for the first
time with a vaccine adverse event that can be predicted. A serolog-
ical test used by Sanofi, the NS1dengue ELISA, was able retrospec-
tively to identify seronegative vaccinated children based upon
absence of DENV NS1 antibodies [25]. Accordingly, some of us rec-
ommended that high risk children be identified and placed on an
‘‘alert” status for clinical attention early after onset of a dengue like
illness.[31] A panel, including the Chair of theWHO Scientific Advi-
sory Group of Experts (SAGE) and the Director of the WHO Initia-
tive for Vaccine Research describe this recommendation as
‘‘misguided.” [32] It is explained the costs of serological testing
would be ‘‘immense” and ‘‘totally disproportionate to the benefit.”
Using Philippine data, the expert panel found severe dengue dis-
ease in seronegative vaccinated children to be ‘‘rare” and, further,
that ‘‘the vast majority of vaccinated children. . .will benefit from
the vaccine.” [30,32]
It should be noted the benefits cited by the WHO group are
based on short term efficacy data. The biological reality is that
seronegatives sensitized by Dengvaxia will be at risk to severe
breakthrough dengue infections for the rest of their lives. In Cuba
secondary DENV 2 disease occurred 20 years after DENV-1 infec-
tions. Persons infected at this long interval had significantly higher
rates of severe disease and death than did those experiencing sec-
ondary DENV-2 infections at a shorter interval.[33] It has been
noted that the phenomenon of heterotypic protection may have
Table 5
Four year projections of occurrence of dengue hospitalizations and severe cases among 880,464 Philippine children who were either given or not given Dengvaxia.
Serostatus At risk DENV infected Vaccinated Not Vaccinated
Hospitalized Severe cases Hospitalized Severe Cases
Seroneg 132,070 63,129a 2241 480 1547 75
Seropos 290,553b 138,884c 2917 597 13,958 3472
Totals 422,623 202,013 5158 1077 15,505 3547
a = monotypic DENV infections.
b = monotypic-immunes.
c = secondary DENV infections.
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phase 3 trials [34]. There is a growing consensus that generic short-
term cross-protection that occurs with sequential DENV infections
means that future dengue vaccine efficacy trials should monitor
dengue illnesses for a period longer than that currently recom-
mended.[15]
The full spectrum of long term risks of giving Dengvaxia either
to dengue seronegative or seropositive individuals is as yet
unknown. We and others have shown that when phase 3 results
were applied to the Philippines, DENV-infection of vaccinated
seropositives contributed the largest fraction of breakthrough dis-
ease.[29,30] Who are these ‘‘seropositives” specifically? To what
degree did adverse outcomes occur in vaccinated children who
were circulating non-dengue flavivirus antibodies? Such children
are labeled ‘‘dengue-immune.” [6] Is this label virologically cor-
rect? Is the risk of breakthrough severe disease related to any
specific prior DENV infection? How do age of the vaccinee and
the interval between vaccination and DENV infection alter out-
comes? Phase 4 surveillance will be crucial to better understand
these biological outcomes in real-life populations.
Reflecting on the risks associated with Dengvaxia, it has been
noted that the administration of a dengue vaccine to healthy
seronegative individuals is an ethical issue. This vaccine prevents
serious disease in some while at the same time it places others
at risk of severe dengue [35]. Despite numerous deliberations by
expert groups, the full range of ethical issues associated with the
identification and management of dengue vaccine SAEs has not
been adequately defined.[15,36–39]4. Recommendations
What can or should be done to assist vaccinated children who
are at risk to severe dengue? Our position is that surveillance for
identifiable adverse events is a phase 4 and public health responsi-
bility. Although, undoubtedly expensive, organized surveillance of
the large vaccinated Philippine population will contribute impor-
tantly to improving our understanding of dengue immunopatho-
genesis attributable to Dengvaxia. Regarding post-vaccination
test costs, critics offered a lengthy negative evaluation of the reli-
ability of the first generation dengue NS1 test applied retrospec-
tively to phase 3 sera [32]. Missing from these comments was
any call to mobilize the leadership and resources needed to
improve and evaluate candidate serological screening tests
[38,40]. Neither WHO nor the manufacturer have moved aggres-
sively to call for the design of a booster vaccine that can remove
vaccinated seronegative individuals from an ‘‘at risk” status. Boos-
ter doses of Dengvaxia are not likely to improve protection. Based
upon published data, doses 2 and 3 did not augment efficacy above
that of the first dose [6]
With respect to continued use of Dengvaxia in licensing coun-
tries we believe the following discussions or implementations be
undertaken: 1) observers should be alert to the occurrence of den-
gue SAEs beyond a period of four years, 2) develop, evaluate andvalidate a serological test that sensitively, specifically and afford-
ably detects immunity to wild-type dengue virus infection, 3) on
emergence of such a test consider the public health importance
of expanding immunization to children under the age of 9 years,
4) discuss whether Dengvaxia can be administered in high endemic-
ity populations without individual serotesting, 5) considering the
lessons learned from Dengvaxia, revise the WHO Guidelines for
Design and Evaluation of Dengue Vaccine Efficacy Trials and 6) in
the event a dengue serological test does emerge determine if the
risks of Dengvaxia SAEs mandate signed consent prior to immuniza-
tion? [41]
This report was written before the pandemic of COVID 19. Some
of the same management issues raised here confront the public
health community in attempting to moderate the burden of dis-
ease. Obtaining and making widely available tests that correctly
identify coronavirus immune status is important. Hopefully, some
of the resources and energy allocated to managing the coronavirus
crisis can also be directed at achieving a full understanding of effi-
cacy and safety issues accompanying Dengvaxia administration.
Lessons should be applied to improve post-vaccination evaluation
and decision-making for future generations of dengue vaccines.5. Contributors
This manuscript resulted from months of discussion of the pub-
lication in July 2018 of data describing an increased risk of severe
dengue in seronegative children given Dengvaxia. The manuscript
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each author.
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